James Wetmore, MD
Nephrology · Minneapolis, MNNPI 1467555383
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,999 of the $47,652 with a category attached, or 75.5%. It is spread thinly across 11 manufacturers, the largest accounting for just 22.1%. Reporting peaked in 2022 at $15,574 and has fallen 54.7% since, to $7,054 in 2025. Among nephrology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $1643.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$11K
- Vifor Fresenius Medical Care Renal Pharma Ltd.$7K
- OPKO Pharmaceuticals, LLC$7K
- GSK$5K
- Aurinia Pharma U.S., Inc.$5K
- Rockwell Medical, Inc.$3K
- plus $9K from 5 others
Across 3 payments — averaging $1896.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$5K
- F. Hoffmann-la Roche AG$690
What the payments were for
- Consulting fees$35,99976%
- Speaking & faculty fees$8,70018%
- Travel & lodging$2,3405%
- Food & beverage$5161%
- Education$970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $10,532 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | 5 | $7,390 |
| OPKO Pharmaceuticals, LLC | 3 | $7,054 |
| GSK | 1 | $5,225 |
| Aurinia Pharma U.S., Inc. | 6 | $5,142 |
| Rockwell Medical, Inc. | 2 | $3,332 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,048 |
| Vifor (international) Ltd. | 1 | $2,856 |
| Vertex | 2 | $2,800 |
| Travere Therapeutics, Inc. | 1 | $145 |
| AstraZeneca | 1 | $126 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,652 in reported general payments places this provider in the 95th percentile of 208 nephrology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 41 | $35,213 |
| Sevelamer Carbonate | 16 | $1,411 |
| Calcitriol | 61 | $1,198 |
| Calcium Acetate | 17 | $1,057 |
| Losartan Potassium | 79 | $1,030 |
| Carvedilol | 69 | $579 |
| Amlodipine Besylate | 51 | $390 |
| Lisinopril | 38 | $378 |
| Hydralazine Hcl | 12 | $367 |
| Potassium Chloride | 11 | $269 |
| Furosemide | 25 | $188 |
| Hydrochlorothiazide | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Minneapolis
- Kirsten JohansenMinneapolis$101K
- Jeffrey KohenMinneapolis$56K
- Robert FoleyMinneapolis$12K
- Jeffrey ConnaireMinneapolis$11K
- Patrick NachmanMinneapolis$7K
- Charles SmithMinneapolis$4K
- Mirna BoumitriMinneapolis$3K
- Jiwan ThapaMinneapolis$3K
- Suzanne SwanMinneapolis$2K
- Arda AkolukMinneapolis$777
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.